Cangrelor

WikiDoc Resources for Cangrelor
Articles
Most recent articles on Cangrelor Most cited articles on Cangrelor Review articles on Cangrelor Articles on Cangrelor in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cangrelor Images of Cangrelor Photos of Cangrelor Podcasts & MP3s on Cangrelor Videos on Cangrelor
Evidence Based Medicine
Cochrane Collaboration on Cangrelor Bandolier on Cangrelor TRIP on Cangrelor
Clinical Trials
Ongoing Trials on Cangrelor at Clinical Trials.gov Trial results on Cangrelor Clinical Trials on Cangrelor at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cangrelor NICE Guidance on Cangrelor NHS PRODIGY Guidance FDA on Cangrelor CDC on Cangrelor
Books
Books on Cangrelor
News
Cangrelor in the news Be alerted to news on Cangrelor News trends on Cangrelor
Commentary
Blogs on Cangrelor
Definitions
Definitions of Cangrelor
Patient Resources / Community
Patient resources on Cangrelor Discussion groups on Cangrelor Patient Handouts on Cangrelor Directions to Hospitals Treating Cangrelor Risk calculators and risk factors for Cangrelor
Healthcare Provider Resources
Symptoms of Cangrelor Causes & Risk Factors for Cangrelor Diagnostic studies for Cangrelor Treatment of Cangrelor
Continuing Medical Education (CME)
CME Programs on Cangrelor
International
Cangrelor en Espanol Cangrelor en Francais
Business
Cangrelor in the Marketplace Patents on Cangrelor
Experimental / Informatics
List of terms related to Cangrelor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cangrelor is a P2Y₁₂ inhibitor under investigation as an antiplatelet drug for intravenous application. Some P2Y₁₂ inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.

Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009. The BRIDGE study, for short term use prior to surgery, continues. The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac stents. Compared with clopidogrel given around the time of stenting, intravenous ADP-receptor blockade with cangrelor significantly reduced the rate of stent thrombosis and myocardial infarction. Reviewers have questioned the methodology of the trial.